The Case Comprehensive Cancer Center (Case CCC), now in its 17 year, provides leadership and oversight for basic cancer research, therapeutic and non-therapeutic cancer clinical trials, prevention, control and population research, as well as community outreach for the major affiliate institutions of Case Western Reserve University: Case School of Medicine, University Hospitals of Cleveland, and the Cleveland Clinic. Located in Cleveland and serving the 3.8 million people in Northern Ohio, members of the Cancer Center manage over 7,000 new cases per year with a high rate of clinical trial access and accrual, operating under a single protocol development and review system, data safety management plan, and a coordinated clinical trials operation. Since the last competitive renewal application, the Center has increased NCI funding by more than 53%, and more than doubled its total peer-reviewed funding. The Center also accrued 877 patients to therapeutic clinical trials in 2005. Significant institutional commitment to Center development resources, faculty recruitment, shared resources, and space assures the Center's continued success and its dynamic approach to multidisciplinary cancer research and therapeutics. The Case CCC has 9 Scientific Programs, 17 shared resources including 6 that are new, and a clinical and behavioral cancer research infrastructure that prioritizes innovative translational research and investigator-initiated clinical trials that cut across the Scientific Programs. These programs include Cancer Genetics, Cell Proliferation and Cell Death, Radiation and Cellular Stress Response, Molecular Mechanisms of Oncogenesis, GU Malignancies (new), Stem Cells and Hematologic Malignancies, Developmental Therapeutics, Cancer Prevention, Control and Population Research, and Aging-Cancer Research (new). The new Shared Resources include Imaging Research, Proteomics, Hybridoma, Transgenic &Targeting, Translational Research, and Practice-Based Research Network. Each of these new Shared Resources is fully operational, supporting the cancer research of multiple members across programs, and providing a critical platform for multidisciplinary and interdisciplinary research. This scientific organization and infrastructure furthers the mission of the Case CCC: to improve the prevention, diagnosis, and therapy of cancer through discovery, evaluation, and dissemination that together reduce cancer morbidity and mortality in Northern Ohio and the Nation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA043703-20S1
Application #
7898333
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1997-08-01
Project End
2012-03-31
Budget Start
2009-07-27
Budget End
2010-03-31
Support Year
20
Fiscal Year
2009
Total Cost
$117,868
Indirect Cost
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Cummings III, Kenneth C; Zimmerman, Nicole M; Maheshwari, Kamal et al. (2018) Epidural compared with non-epidural analgesia and cardiopulmonary complications after colectomy: A retrospective cohort study of 20,880 patients using a national quality database. J Clin Anesth 47:12-18
Thiagarajan, Praveena S; Sinyuk, Maksim; Turaga, Soumya M et al. (2018) Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nat Commun 9:578
Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464
Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726
He, Tian; McColl, Karen; Sakre, Nneha et al. (2018) Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. Mol Oncol 12:2124-2135
Roche, Kathryn L; Nukui, Masatoshi; Krishna, Benjamin A et al. (2018) Selective 4-Thiouracil Labeling of RNA Transcripts within Latently Infected Cells after Infection with Human Cytomegalovirus Expressing Functional Uracil Phosphoribosyltransferase. J Virol 92:
Bedell, Hillary W; Hermann, John K; Ravikumar, Madhumitha et al. (2018) Targeting CD14 on blood derived cells improves intracortical microelectrode performance. Biomaterials 163:163-173
Nagaraj, A B; Wang, Q Q; Joseph, P et al. (2018) Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene 37:403-414
Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2018) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev 27:140-143
Gu, Xiaorong; Ebrahem, Quteba; Mahfouz, Reda Z et al. (2018) Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest 128:4260-4279

Showing the most recent 10 out of 1227 publications